More than a dozen new mouse models of multiple myeloma, which researchers hope will advance understanding and treating the…
Articles by Marisa Wexler, MS
Blocking the activity of a group of proteins called fatty acid-binding proteins (FABPs) may be a useful treatment strategy for…
Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) asking that talquetamab be approved…
The efficacy and safety of Blenrep (belantamab mafodotin) as a treatment for relapsed/refractory multiple myeloma (RRMM) in a real-world…
An advisory panel to the U.S. Food and Drug Administration (FDA) has overwhelmingly decided that the Phase 3 OCEAN clinical…
A combination of the investigational therapy teclistamab and the approved medication Darzalex (daratumumab) reduced the cancer burden for most…
The European Commission has granted full approval to a triple combination therapy of Nexpovio (selinexor) — sold in the U.S. as…
A branch of the European Medicines Agency (EMA) has recommended that Janssen’s investigational therapy Tecvayli (teclistamab) be granted conditional…
CYT-338, an investigational myeloma therapy designed to simultaneously bind to cancer cells and activate immune cells called natural killer…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…